PSP Research LLC Invests $534,000 in Liquidia Corporation $LQDA

PSP Research LLC bought a new position in shares of Liquidia Corporation (NASDAQ:LQDA) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 15,485 shares of the company’s stock, valued at approximately $534,000.

Several other large investors have also made changes to their positions in the company. Covestor Ltd boosted its position in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Liquidia by 7.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock worth $217,000 after acquiring an additional 422 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of Liquidia by 63.6% during the 4th quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock worth $2,179,000 after acquiring an additional 24,555 shares in the last quarter. ProShare Advisors LLC boosted its position in shares of Liquidia by 7.1% during the 4th quarter. ProShare Advisors LLC now owns 11,756 shares of the company’s stock worth $405,000 after acquiring an additional 775 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft acquired a new stake in shares of Liquidia during the 4th quarter worth approximately $224,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Insider Activity at Liquidia

In other Liquidia news, CEO Roger Jeffs sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $57.04, for a total value of $1,426,000.00. Following the sale, the chief executive officer owned 1,198,095 shares in the company, valued at $68,339,338.80. This trade represents a 2.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen M. Bloch sold 318,893 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $50.23, for a total transaction of $16,017,995.39. Following the completion of the sale, the director owned 1,870,042 shares in the company, valued at $93,932,209.66. This represents a 14.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 1,022,713 shares of company stock worth $44,689,753. Corporate insiders own 25.60% of the company’s stock.

Liquidia Stock Performance

Shares of Liquidia stock opened at $59.98 on Wednesday. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $60.55. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The firm has a market capitalization of $5.33 billion, a P/E ratio of 428.46 and a beta of 0.41. The company’s 50 day moving average price is $40.63 and its two-hundred day moving average price is $36.54.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. The company’s quarterly revenue was up 4187.1% compared to the same quarter last year. On average, equities analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on LQDA. Oppenheimer increased their price target on shares of Liquidia from $16.00 to $19.00 and gave the stock an “underperform” rating in a research report on Thursday, March 12th. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. Wall Street Zen upgraded shares of Liquidia from a “buy” rating to a “strong-buy” rating in a research report on Saturday. BTIG Research increased their price target on shares of Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Liquidia presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.33.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).